Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01641991 · ClinicalTrials.gov registry record · Phase 4
Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule
A Phase 4 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 4
- Development phase
- 328
- Enrollment target
NCT01641991 is a Phase 4 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 328 participants.
The verdict
NCT01641991, a Phase 4 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 328 participants
- Enrollment target
Study Summary
A Phase IV, randomized, multicenter trial to assess the immunogenicity and safety of BioThrax® in varying dose regimens with the primary objective of obtaining information on possible dose-sparing strategies in the event of a major biothreat.
Interventions
- BIOLOGICAL BioThrax®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01641991
The ClinicalTrials.gov registry entry for NCT01641991 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 328 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BioThrax® is the first listed.
NCT01641991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01641991 about?
NCT01641991 is a clinical study titled "Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule". A Phase IV, randomized, multicenter trial to assess the immunogenicity and safety of BioThrax® in varying dose regimens with the primary objective of obtaining information on possible dose-sparing strategies in the event of a major biothreat.
What is the current status of trial NCT01641991?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 328 participants. The study started on 2012-07. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01641991?
The interventions under investigation include: BioThrax® (BIOLOGICAL).
Who is sponsoring clinical trial NCT01641991?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.